Management of the website has been transferred from NHMRC to the Commonwealth Department of Health. Disruption to site users as a consequence of this change should be minimal.

Clinical Trial Details

Preventing Cognitive Decline With Metformin

Print record Print record
Trial Information

Broad Health Condition Cognitive Decline

Specific Health Condition

Trial FocusTreatment

Recruitment statusRecruiting

Recruitment Details
Recruitment State

Phase of TrialPhase 3

Trial summary

A randomised control study of metformin in people with mild cognitive impairment and without
diabetes mellitus to determine effects on cognitive decline and neuroimaging over 3 years.

Key inclusion criteria

Inclusion Criteria:

    -  overweight or obese (body mass index >25.0 kg/m2, waist: women>80 cm, men>94cm;

    -  Mild cognitive impairment (Mild Neurocognitive Disorder), based on DSM-5 criteria;

    -  Fasting blood glucose <7.0 mmol/L and HbA1c <6.5%;

    -  Able to undertake neurocognitive testing in English.

    -  Not participating in another trial of drugs or lifestyle modification to reduce
       cognitive decline.

  Exclusion Criteria:

    -  Life-threatening illnesses to preclude participation in a 3-year study;

    -  Contraindications to the use of metformin (severe heart failure or eGFR <40).

Minimum age60 Years

Maximum age80 Years


Can Healthy volunteers participate?Accepts Healthy Volunteers

Contact details and further information

Sponsor Primary Sponsor Type: Other
Primary Sponsor Name: Garvan Institute of Medical Research

Trial website

Trial IDNCT04511416